Immunotherapy-Chemo cocktail shows promise for shrinking cervical tumors before surgery

NCT ID NCT07617818

Not yet recruiting Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing whether adding an immunotherapy drug (QL1706) to standard chemotherapy before surgery can help shrink tumors in women with early-stage cervical cancer (stages IB1-IB3). About 50 participants will receive the combination, then undergo conservative surgery. The main goal is to see how many patients have no cancer left in the removed tissue. Researchers will also track side effects, survival, and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QL1706 (a combination of two immunotherapy drugs, iparomlimab and tuvonralimab) plus cisplatin and paclitaxel chemotherapy
What this could lead to: If successful, this approach could help shrink cervical tumors before surgery, potentially allowing more women to have less extensive surgery and better long-term outcomes.
What could go wrong: This is a small, early-phase trial with only 50 participants and no comparison group. The combination may cause significant side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER IMMUNOTHERAPY NEOADJUVANT THERAPY

More trials for these conditions

Other studies related to the condition(s) this trial covers.